Obseva SA
SIX:OBSN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Obseva SA
SIX:OBSN
|
CH |
|
C
|
CDK Global Inc
LSE:0HQR
|
US |
|
Asahi Songwon Colors Ltd
BSE:532853
|
IN |
|
I
|
Inwido AB (publ)
STO:INWI
|
SE |
|
Alico Inc
NASDAQ:ALCO
|
US |
Obseva SA
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 51 full-time employees. The company went IPO on 2018-07-13. The firm develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 51 full-time employees. The company went IPO on 2018-07-13. The firm develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).
